CNBC June 20, 2024
Angelica Peebles

Key Points

– Gilead’s twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial.

– None of the roughly 2,000 women in the trial who received the lenacapavir shot contracted HIV.

– Gilead needs to replicate the results in another Phase 3 trial before seeking FDA approval. The company expects to share more data later this year or early next year.

– If the results are positive, lenacapavir for PrEP could reach the market as soon as late 2025.

Gilead‘s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.

None of the roughly 2,000 women in the trial who received the lenacapavir shot had contracted HIV by an interim analysis, prompting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Public Health Matters Video: Walmart is Elevating Specialty Pharmacy Services and Enriching HIV Care
Demand for hospital pharmacists dips
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others

Share This Article